Fan L, et al. - In this double-blind, parallel, randomized study, researchers explored the dose-effect relationship of ilaprazole [kind of benzimidazole proton-pump inhibitor] and rabeprazole in the treatment of duodenal ulcer (DU). For this investigation, patients over 18 years of age were treated with rabeprazole 10 mg or ilaprazole 10 mg/5 mg for 4 weeks with at least one endoscopically confirmed active non-malignant DU. In the treatment of DU, Ilaprazole 5 mg is not less than rabeprazole 10 mg, and a dose-effect relationship between 5 mg and 10 mg ilaprazole has been found. After treatment, most patients (80%) became asymptomatic.